麦科田闯关港股上市：2023年实现扭亏为盈，高瓴、深创投等为股东

Core Viewpoint - Shenzhen Maiketian Biomedical Technology Co., Ltd. (referred to as "Maiketian") has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors [1][3]. Company Overview - Maiketian is a global provider of medical solutions, offering an innovative and comprehensive product portfolio to meet clinical needs across various healthcare settings, including hospitals, clinics, and home care [1][3]. - As of June 30, 2025, Maiketian plans to commercialize over 50 life support products, 80 minimally invasive intervention products, and 210 in vitro diagnostic products, with multiple models to cater to diverse applications [3]. Market Presence - Maiketian's products are distributed in over 140 countries and regions globally, with coverage in more than 6,000 hospitals in China, including approximately 90% of tertiary hospitals across 31 provinces, municipalities, and autonomous regions [3]. Company Structure and History - Founded in April 2011, Maiketian was previously known as Shenzhen Yusheng Medical Technology Co., Ltd. The current shareholders do not include the original founders, who are now independent third parties [3][5]. - The company has established five R&D centers and six production centers in China and the UK, with local offices in strategic markets such as the UK, Netherlands, Belgium, Turkey, India, Thailand, Indonesia, Mexico, Brazil, and Colombia [3]. Financial History - Maiketian has undergone multiple rounds of financing since its inception, including a Series A round of RMB 40 million in February 2016, a Series B round of RMB 102 million in March 2017, and a Series C round of RMB 45 million in 2019. In 2023, it secured a new round of equity subscription amounting to approximately RMB 17.75 million [6][8]. Performance Metrics - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 917 million, RMB 1.313 billion, RMB 1.399 billion, and RMB 787 million, respectively. The net profits (losses) for the same periods were approximately -RMB 226 million, -RMB 64.5 million, -RMB 96.6 million, and RMB 40.97 million [9][10]. - Adjusted net profits (losses) based on non-IFRS measures for the same periods were approximately -RMB 1.04 billion, RMB 46.5 million, RMB 20.43 million, and RMB 92.26 million [11].